Want to join the conversation?
Biopharmaceutical company $AMGN said the randomized, double-blind , placebo-controlled Phase 3 Aranesp ARCADE trial met its primary endpoint of reducing incidence of RBC transfusions in anemic patients with low and intermediate-1 risk myelodysplastic syndrome (MDS) at the end of the 25-week study period.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.
Well this is big! I don’t know if it’s someone’s monopoly or genuine excitement, but either way, $CSX is up 23% after market closed. I heard some activist investor is going to blow big money into CSX Corp. Anyone mind explaining?